Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29643214 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A4KCNH2IRAK4ALDH1A1 | |
| SCHEMBL14324634 | 0.83 | ALDH1A1 (0.36) | ALDH1A1HPGDSMN1; SMN2MEN1POLB | |
| SCHEMBL5412735 | 0.83 | ADRA2A (0.51) | SLC6A2SLC6A4KCNH2IRAK4ALDH1A1 | |
| SCHEMBL5249846 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4KCNH2IRAK4ALDH1A1 | |
| SCHEMBL7213720 | 0.82 | MCHR1 (0.38) | SLC6A2SLC6A4KCNH2IRAK4ALDH1A1 | |
| SCHEMBL5414155 | 0.81 | SLC6A2 (0.43) | SLC6A2SLC6A4KCNH2IRAK4ALDH1A1 | |
| SCHEMBL3155854 | 0.81 | SLC6A2 (0.43) | SLC6A2SLC6A4KCNH2IRAK4ALDH1A1 | |
| SCHEMBL11043132 | 0.81 | SLC6A2 (0.43) | SLC6A2SLC6A4KCNH2IRAK4ALDH1A1 | |
| SCHEMBL2094543 | 0.81 | IRAK4 (0.47) | SLC6A2SLC6A4KCNH2IRAK4ALDH1A1 | |
| SCHEMBL2097558 | 0.81 | IRAK4 (0.47) | SLC6A2SLC6A4KCNH2IRAK4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| WO-2025016469-A1 | ALKOXY THIOPHENE ACYL ARYLAMINE COMPOUNDS AND USE THEREOF | 复旦大学 | 2025-01-23 | — | — | WO | disclosed |
| CN-119320385-A | Alkoxy thiophene carboxamide compounds and application thereof | 复旦大学 | 2025-01-17 | — | — | CN | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-112759541-B | Indole-like derivatives and uses thereof | 复旦大学 | 2023-03-17 | — | — | CN | disclosed |
| CN-110114351-B | Heterocyclic inhibitors of MCT4 | 维托尔股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2022-08-11 | — | — | US | disclosed |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2022-04-05 | — | — | US | disclosed |
| CN-112759541-A | Indole-like derivatives and uses thereof | 复旦大学 | 2021-05-07 | — | — | CN | disclosed |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7893264-B2 | viricides comprising phosphinic acid compounds and/or mixed with carriers, nucleoside analogues, interferons or pegylated interferons; treating hepatitis C or a hepatitis C associated disorders in animals; side effect reduction | GILEAD SCIENCES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| EP-2076124-A2 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090170841-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. (US) | 2009-07-02 | — | — | US | disclosed |
| EP-2043658-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008005565-A9 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008131368-A2 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | SLC6A2 344/4885SLC6A4 75/4885KCNH2 1651/4885 |
| US-20080057031-A1 | Antiviral phosphinate compounds | PHOSPHO1, MAVS, ITPA | SLC6A2 3724/4885SLC6A4 2837/4885KCNH2 3710/4885 |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | SLC6A2 3724/4885SLC6A4 2837/4885KCNH2 3710/4885 |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | SLC6A2 344/4885SLC6A4 75/4885KCNH2 1651/4885 |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | SLC6A2 344/4885SLC6A4 75/4885KCNH2 1651/4885 |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | HAVCR2, PHOSPHO1, EIF2AK2 | SLC6A2 3143/4885SLC6A4 3305/4885KCNH2 3845/4885 |
| US-20090170841-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | SLC6A2 2885/4885SLC6A4 1960/4885KCNH2 4642/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | SLC6A2 187/4885SLC6A4 34/4885KCNH2 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.